Arellano et al. (2007) (68)
|
293,253
|
Nested case-control study
(US PharMetrics database)
|
Adjusted OR for lymphoma:
pimecrolimus vs non-use: 0.82 (95% CI 0.42-1.61)
tacrolimus vs non-use: 0.79 (95% CI 0.37-1.71)
low-potency TCS vs non-use: 1.06 (95% CI 0.72-1.57)
high-potency TCS vs non-use: 1.23 (95% CI 0.83-1.84)
|
No increased risk of lymphoma in patients treated with TCS or TCIs,
including pimecrolimus
|
Arana et al. (2011) (72)
|
625,915
|
Nested case-control study
(US PharMetrics database)
|
Adjusted OR for lymphoma:
pimecrolimus vs non-use: 0.76 (95% CI 0.54-1.08)
tacrolimus vs non-use: 1.24 (95% CI 0.80-1.91)
TCS vs non-use: 0.90 (95% CI 0.75-1.07)
|
No increased risk of overall lymphoma in patients with AD treated with
TCS or TCIs, including pimecrolimus. No difference in patients below the
age of 20 years
|
Schneeweiss et al. (2009) (69)
|
1,200,645
|
Nested case-control study (US Ingenix database)
|
RR for lymphoma:
pimecrolimus vs non-use: 1.79 (95% CI 0.92-3.48)
pimecrolimus vs tacrolimus: 1.16 (95% CI 0.74-1.82)
pimecrolimus vs TCS: 1.15 (95% CI 0.49-2.72)
|
No increased risk of lymphoma with pimecrolimus compared to untreated
patients or compared to patients treated with tacrolimus or TCS
|
Arellano et al. (2009) (70)
|
3,500,194
|
A nested case-control study
(UK THIN database)
|
OR for lymphoma:
patients with AD vs patients without AD: 1.83 (95% CI, 1.41-2.36)
TCS vs non-use: 1.46 (95% CI 1.33-1.61)
high-potency TCS vs non-use: 1.80 (95% CI 1.54-2.11)
low-potency TCS vs non-use: 1.36 (95% CI 1.22-1.51)
|
Increased risk of lymphoma in patients with AD, especially severe AD.
TCS use associated with increased risk for lymphoma. No cases of
lymphoma identified in TCI users but number of patients using TCIs was
too low to determine OR
|
Hui et al. (2009) (74)
|
953,064
|
Retrospective cohort study (US Kaiser Permanente database)
|
Adjusted HR for cancer:
pimecrolimus vs non-use: 1.15 (95% Cl 0.99-1.31)
tacrolimus vs non-use: 0.93 (95% CI 0.81-1.07)
Adjusted HR for T-cell lymphoma:
pimecrolimus vs non-use: 2.32 (95% CI 0.89-6.07)
tacrolimus vs non-use: 5.44 (95% CI 2.51-11.79)
|
No increase of overall cancer rate with exposure to tacrolimus or
pimecrolimus. No increased risk of T-cell lymphoma with pimecrolimus.
Use of tacrolimus may be associated with increased risk of T-cell
lymphoma
|